Compare PTY & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PTY | HTFL |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2002 | 2025 |
| Metric | PTY | HTFL |
|---|---|---|
| Price | $11.01 | $48.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $176,034,000.00 |
| Revenue This Year | N/A | $41.41 |
| Revenue Next Year | N/A | $24.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.92 |
| 52 Week Low | $10.65 | $20.13 |
| 52 Week High | $14.69 | $52.22 |
| Indicator | PTY | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 37.74 | 59.55 |
| Support Level | N/A | $46.44 |
| Resistance Level | $11.92 | $51.73 |
| Average True Range (ATR) | 0.20 | 2.06 |
| MACD | -0.02 | -0.45 |
| Stochastic Oscillator | 38.79 | 57.34 |
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on both public or private basis.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.